001     912505
005     20230123110757.0
024 7 _ |a 10.1016/j.jocn.2022.05.031
|2 doi
024 7 _ |a 0967-5868
|2 ISSN
024 7 _ |a 1532-2653
|2 ISSN
024 7 _ |a 2128/33084
|2 Handle
024 7 _ |a 35687921
|2 pmid
024 7 _ |a WOS:000833364000002
|2 WOS
037 _ _ |a FZJ-2022-05678
082 _ _ |a 610
100 1 _ |a Fervers, Philipp
|0 P:(DE-HGF)0
|b 0
|e Corresponding author
245 _ _ |a Meaningful use of imaging resources to rule out cerebral venous sinus thrombosis after ChAdOx1 COVID-19 vaccination: Evaluation of the AHA diagnostic algorithm with a clinical cohort and a systematic data review
260 _ _ |a Burlington, Mass.
|c 2022
|b Harcourt
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1670935283_32695
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Vaccine-induced immune thrombotic thrombocytopenia (VITT) with cerebral venous thrombosis (CVST) is an improbable (0.0005%), however potentially lethal complication after ChAdOx1 vaccination. On the other hand, headache is among the most frequent side effects of ChAdOx1 (29.3%). In September 2021, the American Heart Association (AHA) suggested a diagnostic workflow to facilitate risk-adapted use of imaging resources for patients with neurological symptoms after ChAdOx1. We aimed to evaluate the AHA workflow in a retrospective patient cohort presenting at four primary care hospitals in Germany for neurological complaints after ChAdOx1. Scientific literature was screened for case reports of VITT with CVST after ChAdOx1, published until September 1st, 2021. One-hundred-thirteen consecutive patients (77 female, mean age 38.7 +/− 11.9 years) were evaluated at our institutes, including one case of VITT with CVST. Further 228 case reports of VITT with CVST are published in recent literature, which share thrombocytopenia (225/227 reported) and elevated d-dimer levels (100/101 reported). The AHA workflow would have recognized all VITT cases with CVST (100% sensitivity), the number needed to diagnose (NND) was 1:113. Initial evaluation of thrombocytopenia or elevated d-dimer levels would have lowered the NND to 1:68, without cost of sensitivity. Hence, we suggest that in case of normal thrombocyte and d-dimer levels, the access to further diagnostics should be limited by the established clinical considerations regardless of vaccination history.
536 _ _ |a 5251 - Multilevel Brain Organization and Variability (POF4-525)
|0 G:(DE-HGF)POF4-5251
|c POF4-525
|f POF IV
|x 0
588 _ _ |a Dataset connected to DataCite
700 1 _ |a Kottlors, Jonathan
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Persigehl, Thorsten
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Lennartz, Simon
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Maus, Volker
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Fischer, Sebastian
|0 P:(DE-Juel1)192547
|b 5
|u fzj
700 1 _ |a Styczen, Hanna
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Deuschl, Cornelius
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Schlamann, Marc
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Mpotsaris, Anastasios
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Zubel, Seraphine
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Schroeter, Michael
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Maintz, David
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Fink, Gereon Rudolf
|0 P:(DE-Juel1)131720
|b 13
|u fzj
700 1 _ |a Abdullayev, Nuran
|0 P:(DE-HGF)0
|b 14
773 _ _ |a 10.1016/j.jocn.2022.05.031
|g Vol. 102, p. 5 - 12
|0 PERI:(DE-600)2009190-4
|p 5 - 12
|t Journal of clinical neuroscience
|v 102
|y 2022
|x 0967-5868
856 4 _ |u https://juser.fz-juelich.de/record/912505/files/PDF.pdf
|y OpenAccess
909 C O |o oai:juser.fz-juelich.de:912505
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 5
|6 P:(DE-Juel1)192547
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 13
|6 P:(DE-Juel1)131720
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5251
|x 0
914 1 _ |y 2022
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-30
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-30
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-17
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-17
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J CLIN NEUROSCI : 2021
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-17
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2022-11-17
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21